Cytology is the study of cells using a microscope.
Brachial plexus root avulsion is the most serious type of peripheral nerve injury. Valproic acid has been shown to exert neuroprotective effects and promote neurite outgrowth in several peripheral nerve injury models. However, whether valproic acid can exert its beneficial effect on neurons after brachial plexus avulsion injury is currently unknown.
Avantor™ Performance Materials will display its capabilities as a trusted collaborator and provider of high-quality diagnostic solutions at MEDICA 2013, November 20-23 at the Dusseldorf Fairgrounds in Germany.
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration has approved the Aptima HPV 16 18/45 genotype assay for use on the Company's fully automated Panther system.
Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced preliminary study results suggesting the potential for an RNA-based gene expression test to accurately detect the BRAF V600E gene mutation in thyroid nodule fine needle aspiration (FNA) samples.
Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc.
Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.
PathCentral, a technology-enabled company dedicated to the success of the pathology community, today unveiled its AP Anywhere Express Anatomic Pathology Laboratory Information System.
Researchers from Boston University School of Medicine have pinpointed a genetic signature for chronic obstructive pulmonary disease from airway cells harvested utilizing a minimally invasive procedure.
Trovagene, Inc., today announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus test.
A basic connection of statistics lead a researcher at Women & Infants Hospital of Rhode Island to question whether women should be screened for anal cancer during a regular visit to the gynecologist, and what technique is most effective.
Researchers have adapted the papanicolaou smear test currently used to detect cervical cancer so that it can be used to screen women for endometrial and ovarian cancers.
The National Cancer Coalition (NCC) is expanding its efforts to fight women's cancers in the developing world.
Roche today announces an expanded CE mark indication for the cobas 4800 HPV Test. The newly expanded indication for the cobas® 4800 HPV Test as a primary screen means Pap cytology is no longer required as a co- or pre-test in countries that accept a CE mark.
An unhappy bladder won't be ignored. Frequent urination, pain while urinating, burning while urinating, blood in the urine, and even back pain or pelvic pain can all be symptoms of bladder cancer or other urinary tract problems. The trick, however, is that the absence of urinary symptoms doesn't guarantee a healthy bladder.
Human papillomavirus is a virus that is transmitted through sexual contact. In most cases the virus is transient and causes no harm, however in some cases it can go on to cause pre-cancer lesions and cervical cancer.
Women who undergo treatment for screening-detected cervical intraepithelial neoplasia are more than four times more likely to develop cervical cancer than women with normal smear tests, research suggests.
Testing women to see if they are cured of HPV (the virus that can cause genital warts and cervical cancer) following treatment for abnormal cells on the surface of the cervix is more effective and cheaper than cytology testing (cervical screening) alone, suggests a study published on bmj.com.
Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and The Institute of Photonic Sciences (ICFO) have collaborated on the development of a diagnostic tool that identifies the metastatic ability of breast cancer cells.
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system.
Australian women have a 1 in 9 lifetime risk of developing breast cancer and 1 in every 100 breast cancers occurs in men. In 2012, it is estimated that 14,610 women will be diagnosed with breast cancer, making it the most common cancer affecting women in Australia. However, despite this, few people realise that pathologists arguably play the most important role in the detection and treatment of breast cancer.